

Biocytogen secures \$65M Series C funding

12 April 2018 | News

Its services ranges from the preparation of gene engineered animals to large-scale supply of animal models.



CMB International Capital Corporation Ltd, a wholly-owned subsidiary of China Merchants Bank, recently led a \$65 million series C round in Beijing Biocytogen Co., Ltd., a gene targeted animal model and service supplier.

Existing investors including SDIC Venture Capital Management, 3E Bioventures, Cowin Capital, Oriza Holdings, also participated in the round, according to the company's official WeChat account.

Biocytogen's customers include academic institutions such as Harvard University, University of Tokyo, University of Oxford, Peking University, Tsinghua University, and hospitals, such as Massachusetts General Hospital, Union Hospital, Peking University Hospital, as well as international companies such as Johnson and Johnson, Roche, GSK and Merck.

The company was founded in 2009 by Dr. Yuelei Shenm, a University of Massachusetts School of Medicine graduate with 20 years of experience in immunology, molecular biology and gene knockout model animal production and research. Its services ranges from the preparation of gene engineered animals to large-scale supply of animal models. It also offers preclinical animal studies using gene humanized models, PDX models, and human immune system reconstruction models.